

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



B6

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : G01N 33/68		A1	(11) International Publication Number: WO 00/37944 (43) International Publication Date: 29 June 2000 (29.06.00)
(21) International Application Number: PCT/IB99/02029 (22) International Filing Date: 20 December 1999 (20.12.99) (30) Priority Data: PP 7843 21 December 1998 (21.12.98) AU 09/415,217 12 October 1999 (12.10.99) US (71) Applicant: MONASH UNIVERSITY [AU/AU]; Clayton, VIC 3168 (AU). (72) Inventor: COMPER, Wayne, D.; 387 Old Warrandyte Road, North Ringwood, VIC 3134 (AU). (74) Agent: KIM, Joseph, Hyosuk; McDermott, Will & Emery, 600 13th Street, N.W., Washington, DC 20005-3096 (US).			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: KIDNEY DISEASE DETECTION AND TREATMENT (57) Abstract <p>A method is disclosed for diagnosing early stage of a disease in which an intact protein found in urine is an indicator of the disease. The method includes assaying urine sample to detect the presence of modified protein using either immunological or non-immunological technique. Methods for preventing and treating the disease are also disclosed.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

KIDNEY DISEASE DETECTION AND TREATMENT

5

Field of the Invention

The present invention relates to methods of detecting an early stage of renal disease and/or renal complications of a disease. The invention also relates to preventing and treating the disease.

10

Background of the Invention

The appearance of excess protein such as albumin in the urine is indicative of kidney disease. Diabetic nephropathy is such a disease. By the time the excess albumin is detected, kidney disease has progressed, possibly to a stage where it is irreversible and treatment has little effect. Therefore it is an object of the invention to provide a test that is more sensitive than the currently known radioimmunoassay to detect such a disease as early as possible so that the disease can be either prevented or a treatment protocol commenced early on in the disease.

20

Specific proteinuria, and in particular, albuminuria (micro- and macro-), is a marker of disease including renal disease (glomerulonephritis, bacterial and viral glomerulonephritides, IgA nephropathy and Henoch-Schönlein Purpura, membranoproliferative glomerulonephritis, membranous nephropathy, Sjögren's syndrome, diabetic nephropathy, nephrotic syndrome (minimal change disease, focal glomerulosclerosis and related disorders), acute renal failure, acute tubulointerstitial nephritis, pyelonephritis, GU tract inflammatory disease, Pre-clampsia, renal graft rejection, leprosy, reflux nephropathy, nephrolithiasis), genetic renal disease (medullary cystic, medullar sponge, polycystic kidney disease (autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, tuborous sclerosis), von Hippel-Lindau disease,

30

familial thin-glomerular basement membrane disease, collagen III glomerulopathy, fibronectin glomerulopathy, Alport's syndrome, Fabry's disease, Nail-Patella Syndrome, congenital urologic anomalies), monoclonal gammopathies (multiple myeloma, amyloidosis and related disorders), febrile
5 illness (familial Mediterranean fever, HIV infection -AIDS), inflammatory disease (systemic vasculitides (polyarteritis nodosa, Wegener's granulomatosis, polyarteritis, necrotizing and crescentic glomerulonephritis), polymyositis-dermatomyositis, pancreatitis, rheumatoid arthritis, systemic lupus erythematosus, gout), blood disorders (sickle cell disease, thrombotic thrombocytopenia purpura,
10 hemolytic-uremic syndrome, acute cortical necrosis, renal thromboembolism), trauma and surgery (extensive injury, burns, abdominal and vascular surgery, induction of anaesthesia), drugs (penicillamine, steroids) and drug abuse, malignant disease (epithelial (lung, breast), adenocarcinoma (renal), melanoma, lymphoreticular, multiple myeloma), circulatory disease (myocardial infarction,
15 cardiac failure, peripheral vascular disease, hypertension, coronary heart disease, non-atherosclerotic cardiovascular disease, atherosclerotic cardiovascular disease), skin disease (psoriasis, systemic sclerosis), respiratory disease (COPD, obstructive sleep apnoea, hypoia at high altitude) and endocrine disease (acromegaly, diabetes mellitus, and diabetes insipidus).

20 Kidney disease may result from bacterial infection, allergies, congenital defects, stones, antibiotics, immunosuppressives, antineoplastics, nonsteroidal antiinflammatory drugs, analgesics, heavy metals, tumors, chemicals.

The applicant has found that proteins, including albumin, are normally excreted as a mixture of native protein and fragments that are specifically
25 produced during renal passage (Osicka, T.M. et al. (1996) *Nephrology*, 2,199-212). Proteins are heavily degraded during renal passage by post-glomerular (basement membrane) cells which may include tubular cells. Lysosomes in renal tubular cells may be responsible for the breakdown of proteins excreted during renal passage (see Figure 1). The breakdown products are excreted into the

tubular lumen. In normal individuals, most of the albumin in the urine is fragmented.

When lysosome activity or intracellular processes directing substrates to lysosomes is reduced, more of the high molecular weight, and substantially full
5 length albumin appears in the urine. This reflects an imbalance in the cellular processes in the kidney tissue.

Until now, it was thought that conventional radioimmunoassay was suitable for detecting all (total) of a specific protein in a sample. But the total content of the protein may include more than those that are identifiable by known
10 antibodies using conventional radioimmunoassay (RIA). Currently available radioimmunoassays rely on antibodies to detect proteins such as albumin. Antibody detection is very accurate down to nanogram levels. However, the specificity of the antibodies influences detection of the protein. The antibody detects certain epitopes. If the specific epitope on the albumin is absent, altered or
15 masked, or the albumin is modified in any other way so that the antibody fails to detect the albumin, conventional radioimmunoassays may not provide a true representation of the true amount of albumin present in a urine sample.

Methods of detecting early signs of a disease, including kidney disease, determining a patient's propensity for the disease, preventing the onset of the
20 disease, and treating the disease at the earliest stage possible, as well as a method for determining the total content of a specific protein in a sample, are some of the objects of the invention.

Summary of the Invention

25 The present invention is directed to a method of diagnosing early stage of renal disease and/or renal complications of a disease, comprising:

- (a) separating all of the proteins in a urine sample; and
- (b) detecting a modified form of a protein in the sample, wherein detection
of the modified protein is indicative of an early stage of the renal disease and/or
30 renal complications of a disease.

Although not limited to any particular disease, according to the method of the invention, the disease sought to be diagnosed includes nephropathy, diabetes insipidus, diabetes type I, diabetes II, renal disease (glomerulonephritis, bacterial and viral glomerulonephritides, IgA nephropathy and Henoch-Schönlein Purpura, membranoproliferative glomerulonephritis, membranous nephropathy, Sjögren's syndrome, nephrotic syndrome (minimal change disease, focal glomerulosclerosis and related disorders), acute renal failure, acute tubulointerstitial nephritis, pyelonephritis, GU tract inflammatory disease, Pre-eclampsia, renal graft rejection, leprosy, reflux nephropathy, nephrolithiasis), genetic renal disease (medullary cystic, medullar sponge, polycystic kidney disease (autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, tuberosus sclerosis), von Hippel-Lindau disease, familial thin-glomerular basement membrane disease, collagen III glomerulopathy, fibronectin glomerulopathy, Alport's syndrome, Fabry's disease, Nail-Patella Syndrome, congenital urologic anomalies), monoclonal gammopathies (multiple myeloma, amyloidosis and related disorders), febrile illness (familial Mediterranean fever, HIV infection - AIDS), inflammatory disease (systemic vasculitides (polyarteritis nodosa, Wegener's granulomatosis, polyarteritis, necrotizing and crescentic glomerulonephritis), polymyositis-dermatomyositis, pancreatitis, rheumatoid arthritis, systemic lupus erythematosus, gout), blood disorders (sickle cell disease, thrombotic thrombocytopenia purpura, hemolytic-uremic syndrome, acute cortical necrosis, renal thromboembolism), trauma and surgery (extensive injury, burns, abdominal and vascular surgery, induction of anaesthesia), drugs (penicillamine, steroids) and drug abuse, malignant disease (epithelial (lung, breast), adenocarcinoma (renal), melanoma, lymphoreticular, multiple myeloma), circulatory disease (myocardial infarction, cardiac failure, peripheral vascular disease, hypertension, coronary heart disease, non-atherosclerotic cardiovascular disease, atherosclerotic cardiovascular disease), skin disease (psoriasis, systemic sclerosis), respiratory disease (COPD, obstructive sleep apnoea, hypoia at high

altitude) and endocrine disease (acromegaly, diabetes mellitus, diabetes insipidus).

In addition, the method can be practiced using any protein, preferably, albumin, globulin (α -globulin(α_1 -globulin, α_2 -globulin), β -globulin, γ -globulin),
5 euglobulin, pseudoglobulin I and II, fibrinogen, α_1 acid glycoprotein (orosomucoid), α_1 glycoprotein, α_1 lipoprotein, ceruloplasmin, α_2 19S glycoprotein, β_1 transferrin, β_1 lipoprotein, immunoglobulins A, E, G, and M, horseradish peroxidase, lactate dehydrogenase, glucose oxidase, myoglobin, lysozyme, protein hormone, growth hormone, insulin, or parathyroid hormone.

10 The method can be practiced using non-antibody means, using such methods as chromatography, electrophoresis, or sedimentation, which further include such methods as partition chromatography, adsorption chromatography, paper chromatography, thin-layer chromatography, gas-liquid chromatography, gel chromatography, ion-exchange chromatography, affinity chromatography, or
15 hydrophobic interaction chromatography, moving-boundary electrophoresis, zone electrophoresis, or isoelectric focusing.

In particular, the method of the invention is directed to using a hydrophobic interaction chromatography in a high pressure liquid chromatography (HPLC) apparatus.

20 The present invention is also directed to an antibody detecting method for diagnosing early stage of renal disease and/or renal complications of a disease. The method of the invention is accomplished by assaying for an intact/modified protein that is not normally identifiable in urine using conventional means. The intact/modified protein of the invention is present in the urine sample of a
25 diseased person or a person who is predisposed to a disease before the native protein can be detected. Therefore, the detection of an intact/modified protein in a urine sample indicates at an early stage that the subject is either diseased or predisposed to the disease, even though the subject may otherwise appear to be normal. An assay method of the invention includes detecting an intact/modified
30 protein by an antibody specific for both the modified and unmodified forms of the

protein. Preferably, the antibody is specific for the modified protein. The antibody can be attached to an enzymatic, radioactive, fluorescent or chemiluminescent label, wherein the detecting step comprises radioimmunoassay, immunoradiometric assay, fluorescent immunoassay, enzyme linked
5 immunoassay, or protein A immunoassay.

In the method of the invention, the early stage of the disease is diagnosed when the modified protein is present in the urine in increasing amounts over time, and conventional radioimmunoassay does not detect the modified protein.

The present invention is also directed to an article of matter for diagnosing
10 an early stage of renal disease and/or renal complications of a disease, comprising:

- (a) a container comprising a labeled antibody specific for a modified form of the protein;
- (b) a container comprising reagents for developing antibody reaction; and
- 15 (c) instructions on how to use components (a) and (b) to carry out the diagnosis.

In addition, the present invention is also directed to a method for determining a treatment agent for renal disease and/or renal complications of a disease, comprising:

- 20 (a) administering to a person in need thereof an agent that is suspected of being able to treat the disease;
- (b) obtaining a urine sample from the person; and
- (c) assaying for a modified form of the protein in the sample, wherein either presence or lack of presence of the modified form of the protein in the urine
25 or decreasing amount of the modified form of the protein over time indicates that the agent is a treatment agent for the renal disease and/or renal complications of a disease.

The invention is also directed to a method for treating a person suffering from a disease in which a diseased state is indicated by specific proteinuria,
30 comprising administering a therapeutically effective amount of the treatment

agent obtained according to the above method to a person in need thereof. Preferably, the treatment agent is a lysosome activating compound.

Another object of the invention is to determine the total content of a specific protein in a sample, comprising:

- 5 (a) separating all of the proteins in the sample;
 (b) detecting modified and unmodified forms of the specific protein; and
 (c) integrating the modified and unmodified forms of the specific protein
to determine the total content of the specific protein in the sample.

Preferably, the sample is a biological sample, such as urine.

- 10 These and other objects of the invention will be more fully understood from the following description of the invention, the referenced drawings attached hereto and the claims appended hereto.

Brief Description of the Drawings

- 15 Figure 1 illustrates the progress of filtered intact albumin into tubular cells and breakdown of albumin to provide excreted albumin fragments.

- Figures 2a and 2b illustrate a representative profile of (^3H) HSA in (a) urine and (b) plasma collected from normal, healthy volunteers by size exclusion chromatography. Urine contains mostly fragmented albumin. And plasma
20 contains mostly intact albumin.

 Figure 3 illustrates urine from normal, healthy volunteer showing a fragmented albumin peak, but no intact albumin peak from size exclusion chromatography.

- Figure 4 illustrates urine from a diabetic patient showing both intact and
25 fragmented albumin peaks from size exclusion chromatography.

 Figure 5 illustrates a HPLC profile of albumin alone.

 Figure 6 illustrates the HPLC profile of plasma from normal, healthy volunteer showing albumin peaks.

- Figure 7 shows the HPLC profile of urine from normal, healthy volunteer
30 with fragmented products of albumin but no intact albumin peak.

Figure 8 shows the HPLC profile of a urine sample from a normoalbuminuric diabetic patient showing albumin breakdown products and a small modified albumin peak at approximately 39-44 minutes retention time.

Figure 9 shows the HPLC profile of urine from a normoalbuminuric diabetic patient showing signs of kidney failure and the presence of the characteristic spiked albumin peak at approximately 39-44 minutes retention time.

Figure 10 illustrates a HPLC profile of a normoalbuminuric diabetic patient showing signs of kidney failure and the presence of the characteristic spiked modified albumin peak at approximately 39-44 minutes retention time.

Figure 11 illustrates a HPLC of a macroalbuminuric diabetic patient showing high levels of the normal albumin as well as the characteristic spiked appearance at approximately 39-44 minutes retention time.

Figure 12 illustrates a longitudinal study of a patient in which the modified protein was detected at a time prior to onset of diabetic nephropathy, indicating predisposition to diabetic nephropathy, and the delay in treatment caused by relying on conventional RIA methods.

Figure 13 illustrates a longitudinal study of a patient in which the modified protein was detected at a time prior to onset of diabetic nephropathy, indicating predisposition to diabetic nephropathy, and the delay in treatment caused by relying on conventional RIA methods.

Figure 14 illustrates a longitudinal study of a patient in which the modified protein was detected at a time prior to onset of diabetic nephropathy, indicating predisposition to diabetic nephropathy, and the delay in treatment caused by relying on conventional RIA methods.

Detailed Description of the Invention

The applicant has discovered that when proteins, including major plasma proteins such as albumin and immunoglobulin, are filtered by the kidney they are subsequently degraded by cells in the kidney prior to the material being excreted.

It is likely that filtered proteins are taken up by tubular cells. Tubular cells lie

beyond the kidney filter and come in direct contact with the primary filtrate. When proteins are internalized by the tubular cells, they are directed towards the lysosomes, where they are partially degraded to various size fragments, and then regurgitated to outside the cell. These regurgitated fragments, of which there may
5 be at least 60 different fragments generated from any one particular type of protein, are then excreted into the urine.

The applicant has discovered that in renal disease fragmentation of proteins is inhibited. This means that substantially full-length filtered proteins will be excreted in a person suffering from renal disease. This transition from
10 fragmentation to inhibition of fragmentation of excreted proteins is a basis for the development of new drugs and diagnostic assays. For example, initial changes that occur with the onset of renal complications in diabetes are associated with a change in the fragmentation profile of excreted albumin. This leads to an apparent microalbuminuria which is synonymous with the development of diabetic
15 nephropathy. It is likely that this is due to an inhibition in the lysosomal activity of tubular cells in diabetes. Thus, drugs can be formulated to turn on lysosomal activity in diabetes where renal complications are occurring. The drugs may also be useful in other renal diseases where lysosomal activities are affected, or in diabetes without renal complications in situations where lysosomal activity is
20 turned off in non renal tissues. Such drugs include antiproliferative drugs, such as anti cancer drugs.

The applicant has discovered a unique assay for detecting modified forms of specific proteins, which are detected in the urine of certain subjects before the unmodified form of the specific protein is detected using conventional assays,
25 such as radioimmunoassays. Detection of the modified protein is predictive of a predisposition to renal disease.

Definitions

"Fragmented protein or fragment albumin" includes post-glomerular
30 breakdown products after chemical, enzymatic or physical breakdown that occurs

during renal passage. These components have a reduced size and/or may have changed hydrophobicity.

"Intact albumin, modified albumin, or modified form of albumin" as used herein means a compound having similar size and structural characteristics to native albumin, wherein the amino acid sequence is substantially the same as the native albumin. It is preferably a filtered intact protein. It elutes at or near the same position as native albumin on high pressure liquid chromatography (HPLC) (Figure 5). However, the structure has been modified biochemically either by minor enzyme mediated modification or addition to its basic structure and/or physically through a change in its three dimensional structure so that it escapes detection by conventionally used anti-albumin antibodies. Biochemical modification may be made by enzymes such as endo- or exo- peptidases. The 3D structure of albumin may have been altered in some way. Ligands may have bound to the albumin, or it may be any combination of these. The modified albumin detected in the method of the invention is not detectable by current and conventional radioimmunoassays using available antibodies.

Conventional anti-albumin antibodies can be purchased from any purveyor of immunochemicals. For example, monoclonal antibody catalog numbers A6684 (clone no. HSA-11), and A2672 (clone no. HSA-9), as well as liquid whole serum, lyophilized fractionates, liquid IgG fraction, and the monoclonal antibodies in liquid ascites fluids form, can be obtained from Sigma, St. Louis, MO, as found in the Immunochemicals section at pages 1151-1152 in the 1994 Sigma - Biochemicals Organic Compounds for Research and Diagnostic Reagents catalog.

As used herein, intact/modified albumin includes albumin that is substantially full-length, fragmented, chemically modified, or physically modified. As used herein, intact/modified albumin is meant to indicate albumin that is less than, equal to, or greater in molecular weight than the full-length albumin, and elutes at or near the native albumin position in a separation medium, such as chromatography, preferably HPLC, and most preferably hydrophobicity

HPLC. As used herein, fragmented albumin is meant to refer to the fragment of albumin that is not detected by conventional anti-albumin antibody, and its presence is detected in diagnosing an early stage of renal disease and/or renal complications of a disease. The detection of the presence of intact/modified
5 albumin is an indication of a predisposition to renal disease.

"Intact protein, modified protein or modified form of a protein" as used herein includes those forms of substantially full-length protein which are undetectable by conventional radioimmunoassay. The protein includes, but is not limited to, albumins, globulins (α -globulin(α_1 -globulin, α_2 -globulin), β -
10 globulins, γ -globulins), euglobulins, pseudoglobulin I and II, fibrinogen, α_1 acid glycoprotein (orosomucoid), α_1 glycoprotein, α_1 lipoproteins, ceruloplasmin, α_2 19S glycoprotein, β_1 transferrin, β_1 lipoprotein, immunoglobulins A, E, G, and M, protein hormones including growth hormone, insulin, parathyroid hormone and other proteins including horseradish peroxidase, lactate dehydrogenase, glucose
15 oxidase, myoglobin, and lysozyme.

"Kidney disease" as used herein includes any malfunction of the kidney. Kidney disease may be identified by the presence of intact or modified albumin in the urine. Preferably, an early diagnosis of the kidney disease may be made by detecting the presence of modified protein in the urine, or an increase in the
20 modified protein in the urine over time.

"Low lysosome activity" as used herein is compared against normal levels of lysosome activity and/or lysosome machinery that traffics protein to the lysosome in a normal individual. The activity is insufficient for the lysosome to fragment proteins so that intact protein is excreted at a greater amount than at
25 normally low levels.

"Lysosome-activating compound" as used herein refers to a compound that is beneficial to reactivation of the lysosome. The compound may work directly or indirectly on the lysosome resulting in activation of lysosomal function. These compounds may be selected from the group including, but not

limited to, anticancer compounds, antiproliferation compounds, paracetamol, vitamin A (retinoic acid) or derivatives of retinol.

"Macroalbuminuria" is a condition where an individual excretes greater than 200 μg albumin/min in the urine as measured by conventional
5 radioimmunoassay (RIA).

"Microalbuminuria" is a condition where an individual excretes at least 20 μg albumin/min in the urine as measured by conventional radioimmunoassay (RIA). RIA measures down to 15.6 ng/ml and is able to measure albumin in urine of normal subjects who have clearance of less than 6 $\mu\text{g}/\text{min}$. However, when
10 albumin excretion exceeds 20 $\mu\text{g}/\text{min}$, treatment of the kidney disease is limited and full recovery is difficult from this point.

"Microalbuminuric" as used herein is a condition when albumin is detected in the urine at an excretion rate of at least 20 $\mu\text{g}/\text{min}$ as measured by conventional RIA.

15 As used herein, "native" and "unmodified" are used interchangeably to describe a protein that is naturally found in an organism, preferably a human, which has not been modified by the filtering process of the renal glomeruli.

"Normal individual" as used herein is an individual who does not have a disease in which intact protein found in urine is an indicator of the disease.
20 Preferably, the disease is kidney disease.

"Normal levels of lysosome activity" are levels of lysosome activity found in undiseased kidney of a normal individual.

"Normoalbuminuric" as used herein means a condition where albumin is excreted in the urine and is not detectable by RIA, or less than 20 $\mu\text{g}/\text{min}$ (as
25 measured by RIA) is excreted.

"Propensity for a disease" as used herein means that a disease may result in an individual as judged by a determination of the presence and excretion rate of a modified protein such as modified albumin.

"Proteinuria" as used herein is the existence of protein in the urine, usually in the form of albumin, a protein that is soluble in water and can be coagulated by heat. Related to this, "specific proteinuria" refers to the existence of a particular protein in the urine.

5 "Radioimmunoassay" as used herein is a method for detection and measurement of substances using radioactively labeled specific antibodies or antigens.

"Reactivation of the lysosome" as used herein includes an activation of lysosome activity preferably so that breakdown of proteins, particularly albumin,
10 is increased compared with an inactivated state of the lysosome.

"Restore" as used herein means to restore in full or in part so that the component being restored has an improved function compared with its previous function.

"Total protein" as used herein refers to a particular filtered protein present
15 in native, unmodified, modified or fragmented form that is excreted in urine. It includes protein that is not detected by conventional radioimmunoassay or conventional methods which are currently available to detect the protein. Preferably the protein is albumin.

According to the present invention, the diseases to be treated include, but
20 are not limited to renal disease (glomerulonephritis, bacterial and viral glomerulonephritides, IgA nephropathy and Henoch-Schönlein Purpura, membranoproliferative glomerulonephritis, membranous nephropathy, Sjögren's syndrome, diabetic nephropathy, nephrotic syndrome (minimal change disease, focal glomerulosclerosis, and related disorders), acute renal failure, acute
25 tubulointerstitial nephritis, pyelonephritis, GU tract inflammatory disease, Pre-clampsia, renal graft rejection, leprosy, reflux nephropathy, nephrolithiasis), genetic renal disease (medullary cystic, medullar sponge, polycystic kidney disease (autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, tuborous sclerosis), von Hippel-Lindau disease,
30 familial thin-glomerular basement membrane disease, collagen III

glomerulopathy, fibronectin glomerulopathy, Alport's syndrome, Fabry's disease, Nail-Patella Syndrome, congenital urologic anomalies)

In one aspect of the invention, there is provided a method for determining a propensity for or early diagnosis of renal disease and/or renal complications of a disease. The method includes determining a change in the albumin content in a urine sample. The disease may be a kidney disease, although not necessarily limited to a kidney disease.

In the method of the invention, albumin is used herein only as an example of a protein to be detected in urine. When the albumin in a patient is analysed by conventional RIA, it is expected that a normoalbuminuric patient or normal individual would have albumin in the urine in the range of 3-10 $\mu\text{g}/\text{min}$ in young people and greater in older people. However, normoalbuminuric patients also show levels of albumin in the urine if measured by HPLC. Applicant has found that these levels may be in the order of 5 $\mu\text{g}/\text{min}$. As kidney disease progresses, the level of intact/modified albumin will increase to microalbuminuria levels in the order of 20 to 200 $\mu\text{g}/\text{min}$ as determined by RIA. This will be much higher when determined by HPLC or a method that determines total albumin, including modified albumin. By monitoring the increase in intact/modified albumin, early signs of kidney disease may be detected. However, these levels are not detectable by the methods currently available such as radioimmunoassay using antibodies currently commercially in use, possibly for the reason that antibodies detect certain epitopes. If the albumin is modified in any way as described above, the epitope may be destroyed thereby leaving the modified albumin undetectable.

A patient suspected of having diabetic kidney disease will not show signs of kidney degeneration until well after 10 to 15 years when albumin is detected by currently available methods such as RIA methods. Urinary excretion rates of at least 20 $\mu\text{g}/\text{min}$ may be detected by RIA when an individual enters a microalbuminuric state. Again, by observing the excretion of modified albumin, a change in the kidney and possibly onset of a kidney disease may be detected.

A normoalbuminuric subject, or normoalbuminuric diabetic patient may continue to have a low albumin excretion rate of less than 20 $\mu\text{g}/\text{min}$ as determined by RIA, for many years. The presence of albumin in the urine is a sign that functions of the kidney may be impaired. Once this level begins to
5 change, treatment may be initiated.

In a normal individual a small amount of albumin is detectable in the urine. Total filtered albumin appears mainly as fragmented albumin in urine. Some albumin may be detected in normoalbuminuric individuals. However, the excretion rate of albumin in urine in a normoalbuminuric individual may be as
10 low as 5 $\mu\text{g}/\text{min}$. This level is generally detectable by RIA.

The modified protein of the invention can be detected by a variety of methods that are well-known in the art, including, but not limited to chromatography, electrophoresis and sedimentation, or a combination of these, which are described in Karger BL, Hancock WS (eds.) *High Resolution*
15 *Separation and Analysis of biological Macromolecules. Part A Fundamentals in Methods in Enzymology*, Vol. 270, 1996, Academic Press, San Diego, California, USA; Karger BL, Hancock WS (eds.) *High Resolution Separation and Analysis of biological Macromolecules. Part B Applications in Methods in Enzymology*, Vol.
271, 1996, Academic Press, San Diego, California, USA; or Harding SE, Rowe,
20 AJ, Horton JC (eds.) *Analytical Ultracentrifugation in Biochemistry and Polymer Science*. 1992, Royal Soc. Chemistry, Cambridge, UK, which references are incorporated herein by reference in their entirety.

The electrophoresis method includes, but is not limited to, moving-boundary electrophoresis, zone electrophoresis, and isoelectric focusing.

25 The chromatography method includes, but is not limited to, partition chromatography, adsorption chromatography, paper chromatography, thin-layer chromatography, gas-liquid chromatography, gel chromatography, ion-exchange chromatography, affinity chromatography, and hydrophobic interaction chromatography. Preferably, the method is a sizing gel chromatography and

hydrophobic interaction chromatography. More preferably, the method is hydrophobic interaction chromatography using a HPLC column.

Applicant has found that among diabetics, a normoalbuminuric diabetic patient has almost undetectable levels of albumin when analysed by conventional RIA. They appear to be normal. However, when the urine is tested by HPLC, the levels of modified albumin are much greater than found in a normal individual. This difference in albumin may be attributed to the inability of conventional RIA's to adequately detect all albumin (total albumin) in intact or modified forms. Thus, HPLC is preferred for generating a fragmentation profile. A fragmentation profile on HPLC is characterized by a series of peaks representing a number of species of albumin in intact or modified forms.

In a preferred aspect of the present invention, the method of determining a propensity for or early diagnosis of a kidney disease in a subject is determined before the subject becomes microalbuminuric.

Measuring albumin content in a sample by an HPLC method of the present invention may provide different results from its measurement by conventional RIA. In the HPLC technique, a low level of albumin is observed in normal individuals. When the level of modified albumin begins to be detected and its level increases, and progresses toward microalbuminuria then a patient can be determined to have a propensity for kidney disease.

In a normal individual, the HPLC generated fragmentation profile is characterized by the absence of a peak in a region where full-length native albumin elutes. Instead, multiple fragmented albumin is detectable. A pure protein product (unmodified) produces essentially a single peak. For example, using a hydrophobicity HPLC, albumin was observed to elute in the range of 39-44 minutes (Figure 5). Thus, a normal individual would provide a distinct fragmentation profile indicative of an absence of kidney disease or no propensity for a kidney disease. However, as kidney disease progresses, an increasing amount of modified albumin first, and then native form later are detectable. The fragmentation profile begins to change and more products in the region of full-

length albumin manifests as additional spikes or an enlarged peak indicative of more intact/modified albumin in the urine.

In a HPLC generated fragmentation profile of a urine sample, the modified albumin may appear in a region where native albumin elutes but may be manifest
5 as multiple peaks indicating the presence of multiple forms of modified albumin.

In a further preferred embodiment, the propensity for kidney disease may be measured by determining the presence of or identifying at least one species of modified albumin. This may be determined or identified by the presence of a specific peak on a HPLC profile, preferably the peak is within the range of
10 position that corresponds to the elution position of the native albumin.

A HPLC column for detecting modified albumin or unmodified albumin may be a hydrophobicity column, such as Zorbax 300 SB-CB (4.6mm x 150 mm). A 50µl sample loop may be used. Elution solvents suitable for HPLC in detecting albumin and its breakdown products may include standard elution solvents such
15 as acetonitrile solvents. Preferably a buffer of water/1% trifluoro acetic acid (TFA) followed by a buffer of 60% acetonitrile/0.09% TFA may be used. A gradient of 0 to 100% of a 60% acetonitrile/0.09% TFA has been found to be suitable.

Suitable HPLC conditions for a hydrophobicity column may be as follows:
20 Solvent A H₂O, 1% trifluoro acetic acid
Solvent B 60% acetonitrile, 0.09% TFA

Solvent A2 99.96>00.00:49.58min
Pressure 9.014Mpascalls (~1100psi)
25 Solvent B2 0.04>100.0:49.58min
Pressure 7.154Mpascalls

The wavelength used in HPLC may be approximately 214 nm.

Modified albumin may elute between 39-44 minutes (Figure 5). Albumin
30 fragments may elute much earlier, mainly at less than 20 minutes.

The method for determining the propensity for kidney disease is applicable to any individual. Kidney disease may be caused by a number of factors including bacterial infection, allergic, congenital defects, stones, tumors, chemicals or from diabetes. Preferably, the method is applicable for determining a propensity for kidney disease in diabetic patients that may progress to a kidney disease. Preferably, the individual is a normoalbuminuric diabetic. However, normal individuals may be monitored for propensity for the disease by determining increased levels of intact or modified albumin in the urine.

The method of the invention can be carried out using non-antibody separation procedures as described above. However, antibody specific for modified protein may also be used to detect the presence of the modified protein.

The antibody to the modified protein may be obtained using the following method. The procedure is described specifically for albumin by way of example only, and can be readily applied to antibody production against any other protein in the urine. The method seeks to determine which modified albumin molecule is the most sensitive marker to identify diabetic patients, for example, who will progress to kidney complications.

The modified albumin is characterized by carrying out a quantitative separation of the modified albumin molecules, such as by preparative HPLC. The modified proteins are analyzed for ligand binding, such as glycation. Subsequently, amino acid sequence of the individual modified protein is determined, preferably by mass spectrometry using methods described in Karger BL, Hancock WS (eds.) *High Resolution Separation and Analysis of biological Macromolecules. Part A Fundamentals in Methods in Enzymology*, Vol. 270, 1996, Academic Press, San Diego, California, USA; or Karger BL, Hancock WS (eds.) *High Resolution Separation and Analysis of biological Macromolecules. Part B Applications in Methods in Enzymology*, Vol. 271, 1996, Academic Press, San Diego, California, USA, for example, which references are incorporated herein by reference in their entirety. In a preferred embodiment, there may be about 3 to 4 modified albumin species.

The method of generating antibody against the modified albumin seeks to develop a diagnostic immunoassay for the modified albumin that predicts those diabetic patients, for example, that progress to kidney complications. To accomplish this, sufficient quantities of modified albumin is prepared by HPLC.

- 5 Antibodies are made by sequential injection of the modified albumin in an animal such as a rabbit, to generate good titer, and the antibodies are isolated using conventional techniques using methods described in Goding JW, *Monoclonal Antibodies: Principles and Practice. Production and Application of Monoclonal Antibodies in Cell Biology, Biochemistry and Immunology*, 2nd Edition 1986, Academic Press, London, UK; or Johnstone A, Thorpe R, *Immunochemistry in Practice*, 3rd edition 1996, Blackwell Science Ltd, Oxford, UK, for example, which references are incorporated herein by reference in their entirety. The obtained antibodies may be polyclonal antibodies or monoclonal antibodies.
- 10

- Preferably, at least one species of a modified albumin is isolated and identified for use in determining a propensity for kidney disease. The isolated species may be used to generate antibodies for use in immunoassays. The antibodies may be tagged with an enzymatic, radioactive, fluorescent or chemiluminescent label. The detection method may include, but is not limited to radioimmunoassay, immunoradiometric assay, fluorescent immunoassay, enzyme linked immunoassay, and protein A immunoassay. The assays may be carried out in the manner described in Goding JW, *Monoclonal Antibodies: Principles and Practice. Production and Application of Monoclonal Antibodies in Cell Biology, Biochemistry and Immunology*. 2nd Edition 1986, Academic Press, London, UK; Johnstone A, Thorpe R, *Immunochemistry in Practice*, 3rd edition 1996, Blackwell Science Ltd, Oxford, UK; or Price CP, Newman DJ (eds.) *Principles and Practice of Immunoassay*, 2nd Edition, 1997 Stockton Press, New York, NY, USA, for example, which references are incorporated herein by reference in their entirety.
- 15
- 20
- 25

- It is an object of this invention to provide an article of matter or a kit for rapidly and accurately determining the presence or absence of modified protein
- 30

such as modified albumin, in a sample quantitatively or non-quantitatively as desired. Each component of the kit(s) may be individually packaged in its own suitable container. The individual container may also be labeled in a manner which identifies the contents. Moreover, the individually packaged components
5 may be placed in a larger container capable of holding all desired components. Associated with the kit may be instructions which explain how to use the kit. These instructions may be written on or attached to the kit.

The invention is also directed to a method of determining a treatment agent for renal disease and/or renal complications of a disease, comprising:

10 (a) administering to a person an agent that is suspected of being able to treat the disease;

(b) obtaining a urine sample from the person; and

(c) assaying for the modified form of the protein in the sample, wherein either the presence of or lack of presence of a modified form of the
15 protein in the urine or decreasing amount of the modified form of the protein over time indicates that the agent is a treatment agent for the disease. The treatment agent may be a lysosome activating agent that may act directly or indirectly to activate lysosome, and thereby cause the lysosome to digest post-glomerular filtered proteins, which is a sign of a healthy kidney.

20 The process of trafficking of proteins to the lysosomes plays a role in the mechanism of albuminuria in diabetes. An intracellular molecule that is involved in trafficking is protein kinase C (PKC). It is contemplated that a drug or agent can be formulated that will activate lysosomal trafficking or inhibit PKC.

Accordingly, in one aspect of the present invention, there is provided a
25 lysosome-activating compound for use in reactivating lysosomes or processes that direct substrates to the lysosome or products away from the lysosome.

In another aspect of the present invention, there is provided a composition comprising a lysosome-activating compound and a carrier.

In yet another aspect of the invention there is provided a method of preventing or treating kidney disease, said method including administering an effective amount of a lysosome-activating compound to a subject.

In yet another aspect of the present invention, there is provided a method
5 of screening a multiplicity of compounds to identify a compound capable of activating lysosomes or processes that direct substrates to the lysosome or products away from the lysosome, said method including the steps of:

(a) exposing said compound to a lysosome and assaying said
10 compound for the ability to activate a lysosome wherein said lysosome when activated has a changed activity;

(b) assaying for the ability to restore a cellular process to substantially
normal levels in kidney tissue, wherein said kidney tissue has a low lysosome activity; and/or

(c) assaying for the ability to restore tissue turnover to substantially
15 normal levels in kidney tissue, wherein said kidney tissue has low lysosome activity.

Lysosomes may be associated with the breakdown of proteins, particularly albumin, in the kidney. In cases of microalbuminuria, substantial amounts of albumin escape lysosomal breakdown possibly due to a deactivated lysosome.
20 Restoration of lysosomal breakdown may restore the balance in the kidney of cellular processes and tissue turnover.

A lysosome-activating compound may be a compound that acts directly or indirectly on the lysosome. By acting indirectly, the compound may act on a component which influences the activity of the lysosome. Nevertheless, the
25 outcome results in an activation of the lysosome, thereby providing enhanced protein breakdown.

In another aspect of the present invention, there is provided a composition comprising a lysosome-activating compound and a carrier.

The composition may be a physiologically acceptable or pharmaceutically
30 acceptable composition. However, it will be a composition which allows for

stable storage of the lysosome activating compound. Where the composition is a pharmaceutically acceptable composition, it may be suitable for use in a method of preventing or treating kidney disease.

In yet another aspect of the invention there is provided a method of preventing or treating kidney disease, said method including administering an effective amount of a lysosome-activating compound to a subject.

As described above, the lysosome-activating compound may act by reactivating the lysosome so that cellular processes and tissue turnover are restored fully or in part, thereby resulting in the kidney being restored partially or fully. In any case, administering a lysosome activating compound to an animal having kidney disease may restore lysosome activity fully or in part.

Methods of administering may be oral or parenteral. Oral may include administering with tablets, capsules, powders, syrups, etc. Parenteral administration may include intravenous, intramuscular, subcutaneous or intraperitoneal routes.

The changed activity of the lysosome is preferably a change which enhances the activity of the lysosome so that albumin breakdown is improved. The ability to not only activate lysosome but also improve cellular processes and/or tissue turnover is a characteristic of the most desirable lysosome activating compound. Preferably, it is desired to use the lysosome activating compound to restore kidney function.

In another aspect of the present invention there is provided a method for preventing kidney disease in a subject, said method including:

- (a) measuring the total albumin content in a urine sample;
- (b) determining a change in the amount of intact albumin in the urine that has been modified so as to be not detectable by conventional RIA methods wherein the change is indicative of a propensity for kidney disease; and treating the animal for a kidney disease when a change is determined.

The following examples are offered by way of illustration of the present invention, and not by way of limitation.

EXAMPLES

Example 1: Size Exclusion Chromatography of Human Serum Albumin (HSA)

Normal, healthy volunteers were used to provide urine for analyzing the
5 distribution of albumin in their urine.

$^3\text{H}[\text{HSA}]$ (Human Serum Albumin) was injected into healthy volunteers
and urine and plasma were collected and analyzed by size exclusion
chromatography using a G-100 column. The column was eluted with PBS
(pH=7.4) at 20 ml/hr at 4°C. The void volume (V_o) of the column was
10 determined with blue dextran T2000 and the total volume with tritiated water.

Tritium radioactivity was determined in 1 ml aqueous samples with 3 ml
scintillant and measured on a Wallac 1410 liquid scintillation counter (Wallac
Turku, Finland).

Figure 2 illustrates the distribution of albumin in urine and in plasma.
15

Example 2: Albumin Excretion in a normal, healthy volunteer and diabetic patient

$^3\text{H}[\text{HSA}]$ as used in Example 1 was injected into a normal, healthy
volunteer and a diabetic patient. Samples of urine were collected and $^3\text{H}[\text{HSA}]$
20 was determined as in Example 1.

The normal, healthy volunteer (Figure 3) shows the excretion of fragments
of albumin on a size exclusion chromatography as performed in Example 1.

The diabetic patient (Figure 4) shows the presence of substantially full-
length and fragmented albumin on size exclusion chromatography. However,
25 excretion rates of albumin detectable by these methods were in the order of 5
 $\mu\text{g}/\text{min}$ (control) and 1457 $\mu\text{g}/\text{min}$ (diabetic).

Example 3: Determination of Total Albumin, and Intact/Modified Albumin on HPLC.

Urine samples were collected from normal, healthy volunteer, normoalbuminuric diabetic patients and from macroalbuminuric patients. Urine
5 was collected midstream in 50 ml urine specimen containers. The urine was frozen until further use. Prior to HPLC analysis the urine was centrifuged at 5000 g.

Samples were analysed on HPLC using a hydrophobicity column Zorbax 300 SB-CB (4.6 mmx 150 mm). A 50 µl sample loop was used.

10 Samples were eluted from the columns using the following conditions.

Solvent A H₂O, 1% trifluoro acetic acid

Solvent B 60% acetonitrile, 0.09% TFA

Solvent A2 99.96>00.00:49.58min

15 Pressure 9.014Mpascalls (~1100psi)

Solvent B2 0.04>100.0:49.58min

Pressure 7.154Mpascalls

A wavelength of 214 nm was used.

20

Results

Figure 5 illustrates a HPLC profile of albumin alone. Essentially a single peak which elutes at approximately 39-44 minutes retention time was obtained.

Figure 6 illustrates a HPLC profile of plasma showing a distinct albumin
25 peak at approximately 39-44 minutes as well as other peaks corresponding to other plasma proteins.

Figure 7 illustrates a HPLC profile of a normal, healthy volunteer showing no albumin peak in the urine sample. This individual breaks down the albumin excreted into the urine possibly via an active lysosome. Substantial fragmented

products were evident showing prominence of some species, particularly of a species at approximately less than 14.5 minutes retention time.

When urine from a normoalbuminuric diabetic patient (with an albumin excretion rate of 8.07 $\mu\text{g}/\text{min}$, as measured by RIA) is analysed (Figure 8), small amounts of modified albumin eluting at approximately 39-44 minutes retention time is evident. Whereas conventional test indicates the presence of <6 mg/l of albumin in the urine sample, the method of the invention showed that the true albumin content in the urine sample was 26.7 mg/l. Treatment for the disease should have begun on this individual. Albumin by-products or fragmented albumin is present as in the normal, healthy volunteer.

Another urine sample from normoalbuminuric diabetic patient (with albumin excretion rate of 17.04 $\mu\text{g}/\text{min}$) was analyzed (Figure 9). RIA tests show albumin excreted in the urine for this patient. However, on HPLC (Figure 9) an albumin or modified albumin peak is evident at approximately 39-44 minutes retention time. Whereas conventional test indicates the presence of <6 mg/l of albumin in the urine sample, the method of the invention showed that the true albumin content in the urine sample was 81.3 mg/l. Treatment for the disease should have begun on this individual. This peak begins to show a multiple peaked appearance. A smaller peak corresponding to intact albumin shows that modified albumin may represent the peak at 39-44 minutes. The presence of this albumin peak compared with the profile of a normal, healthy volunteer having no albumin peak shows a change in the detectable levels of the amount of intact/modified albumin. This may signal a propensity for a kidney disease.

A further urine sample from a normoalbuminuric diabetic patient (with an albumin excretion rate of 4.37 $\mu\text{g}/\text{min}$) was analyzed, and the HPLC profile is illustrated in Figure 10. Again, modified albumin was detected at approximately 39-44 minutes retention time showing multiple peaks. This patient again did register normal albumin by RIA. Whereas conventional test indicates the presence of <6 mg/l of albumin in the urine sample, the method of the invention showed that the true albumin content in the urine sample was 491 mg/l. Treatment for the

disease should have begun on this individual. It is clear that modified albumin assessment is necessary to identify these changes. This patient would be determined to have a propensity for kidney disease. As kidney disease progresses, the modified albumin peak will continue to increase.

5 This is shown in Figure 11 where a urine sample of a macroalbuminuric patient was analyzed. A quite significant albumin peak at approximately 39-44 minutes retention time showing multiple peaks was evident. The patient's albumin content was 1796 mg/l. Treatment for this individual is in progress.

10 The method of the invention results in early detection of a propensity for a renal disease as illustrated by the longitudinal studies in Figures 12-14. Figures 12-14 show situations in which the ACE inhibitor treatment for diabetes was begun later than it should have had the modified albumin detection method of the invention been used. Detecting modified protein using the method according to the invention is a more effective method for predicting the onset of a renal disease
15 than using conventional RIA.

 All of the references cited herein are incorporated by reference in their entirety.

 Finally, it is to be understood that various other modifications and/or alterations may be made without departing from the spirit of the present invention
20 as outlined herein.

What is Claimed Is:

1. A method of diagnosing an early stage of renal disease and/or renal complications of a disease, comprising:

5 (a) separating all of the proteins in a urine sample; and

(b) detecting a modified form of a protein in the sample, wherein detection of the modified protein is indicative of an early stage of the renal disease and/or renal complications of a disease.

2. The method according to claim 1, wherein the disease comprises
10 nephropathy, diabetes insipidus, diabetes type I, diabetes II, renal disease (glomerulonephritis, bacterial and viral glomerulonephritides, IgA nephropathy and Henoch-Schönlein Purpura, membranoproliferative glomerulonephritis, membranous nephropathy, Sjögren's syndrome, nephrotic syndrome (minimal change disease, focal glomerulosclerosis and related disorders), acute renal
15 failure, acute tubulointerstitial nephritis, pyelonephritis, GU tract inflammatory disease, Pre-clampsia, renal graft rejection, leprosy, reflux nephropathy, nephrolithiasis), genetic renal disease (medullary cystic, medullar sponge, polycystic kidney disease (autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, tuborous sclerosis), von Hippel-
20 Lindau disease, familial thin-glomerular basement membrane disease, collagen III glomerulopathy, fibronectin glomerulopathy, Alport's syndrome, Fabry's disease, Nail-Patella Syndrome, congenital urologic anomalies), monoclonal gammopathies (multiple myeloma, amyloidosis and related disorders), febrile illness (familial Mediterranean fever, HIV infection -AIDS), inflammatory
25 disease (systemic vasculitides (polyarteritis nodosa, Wegener's granulomatosis, polyarteritis, necrotizing and crescentic glomerulonephritis), polymyositis-dermatomyositis, pancreatitis, rheumatoid arthritis, systemic lupus erythematosus,

gout), blood disorders (sickle cell disease, thrombotic thrombocytopenia purpura, hemolytic-uremic syndrome, acute cortical necrosis, renal thromboembolism), trauma and surgery (extensive injury, burns, abdominal and vascular surgery, induction of anaesthesia), drugs (penicillamine, steroids) and drug abuse, malignant disease (epithelial (lung, breast), adenocarcinoma (renal), melanoma, lymphoreticular, multiple myeloma), circulatory disease (myocardial infarction, cardiac failure, peripheral vascular disease, hypertension, coronary heart disease, non-atherosclerotic cardiovascular disease, atherosclerotic cardiovascular disease), skin disease (psoriasis, systemic sclerosis), respiratory disease (COPD, obstructive sleep apnoea, hypoxia at high altitude) and endocrine disease (acromegaly, diabetes mellitus, diabetes insipidus).

3. The method according to claim 1, wherein the protein comprises albumin, globulin (α -globulin(α_1 -globulin, α_2 -globulin), β -globulin, γ -globulin), euglobulin, pseudoglobulin I and II, fibrinogen, α_1 acid glycoprotein (orosomucoid), α_1 glycoprotein, α_1 lipoprotein, ceruloplasmin, α_2 19S glycoprotein, β_1 transferrin, β_1 lipoprotein, immunoglobulins A, E, G, and M, horseradish peroxidase, lactate dehydrogenase, glucose oxidase, myoglobin, lysozyme, protein hormone, growth hormone, insulin, or parathyroid hormone.

4. The method according to claim 3, wherein the protein is albumin.

5. The method according to claim 1, wherein the modified protein is detected by non-antibody means.

6. The method according to claim 5, wherein said non-antibody means comprises chromatography, electrophoresis, or sedimentation.

7. The method according to claim 6, wherein said non-antibody means comprises partition chromatography, adsorption chromatography, paper chromatography, thin-layer chromatography, gas-liquid chromatography, gel

chromatography, ion-exchange chromatography, affinity chromatography, or hydrophobic interaction chromatography, moving-boundary electrophoresis, zone electrophoresis, or isoelectric focusing.

8. The method according to claim 7, wherein said non-antibody
5 means comprises hydrophobic interaction chromatography.

9. The method according to claim 8, wherein the hydrophobic interaction chromatography is carried out in a high pressure liquid chromatography (HPLC) apparatus.

10. The method according to claim 1, wherein the modified protein is
10 detected by an antibody that is specific for both unmodified and modified forms of the protein.

11. The method according to claim 10, wherein the antibody is specific for the modified protein.

12. The method according to claim 11, wherein the antibody is
15 attached to an enzymatic, radioactive, fluorescent or chemiluminescent label, wherein the detecting step comprises radioimmunoassay, immunoradiometric assay, fluorescent immunoassay, enzyme linked immunoassay, or protein A immunoassay.

13. The method according to claim 1, wherein an early stage of the
20 disease is diagnosed when the modified protein is present in the urine in increasing amounts over time.

14. The method according to claim 1, wherein conventional radioimmunoassay does not detect the modified protein.

15. An article of matter for diagnosing early stage of a disease in
25 which intact protein found in urine is an indicator of the disease, comprising:

(a) a container comprising a labeled antibody specific for a modified form of the protein;

(b) a container comprising reagents for developing an antibody reaction; and

5 (c) instructions on how to use components (a) and (b) to carry out the diagnosis.

16. A method for determining a treatment agent for renal disease and/or renal complications of a disease, comprising:

(a) administering to a person in need thereof an agent that is suspected of
10 being able to treat the disease;

(b) obtaining a urine sample from the person; and

(c) assaying for a modified form of a protein in the sample, wherein either presence of or lack of presence of the modified form of the protein in the urine or decreasing amount of the modified form of the protein over time in the urine
15 indicates that the agent is a treatment agent for the renal disease and/or renal complications of a disease.

17. A method for treating a person suffering from renal disease and/or renal complications of a disease, comprising administering a therapeutically effective amount of the treatment agent obtained according to claim 16 to a
20 person in need thereof.

18. The method according to claim 17, wherein the treatment agent is a lysosome activating compound.

19. A method for determining total content of a specific protein in a sample, comprising:

- (a) separating all of the proteins in the sample;
- (b) detecting modified and unmodified forms of the specific protein; and
- 5 (c) integrating the modified and unmodified forms of the specific protein to determine the total content of the specific protein in the sample.

20. The method according to claim 19, wherein said sample is a biological sample.




FIG. 1

2/14




FIG. 2

3/14




FIG. 3

4/14





FIG. 4

5/14

FIG. 5




Peak Results

#	Name	Ret Time (min)	Area (uV*sec)	Height (uV)	Amount	Int Type
1		4.117	329140	40683		BB
2		4.883	15767507	16240		BB
3		39.467	101020	6703		BB
4		40.000	46216	3171		BB
5		40.733	3138458	242228		BV
6		41.017	13063671	486192		VB
7		43.233	62005	5618		BV
8		43.700	33150	2909		VB
9		48.683	76368	3554		BB

6/14

FIG. 6




Peak Results

#	Name	Ret Time (min)	Area (uV*sec)	Height (uV)	Amount	Int Type
1		4.133	1802825	122050		BB
2		4.933	1874787	51415		BV
3		5.550	2903127	94067		VB
4		14.633	31135	3556		BB
5		15.617	54780	5951		BV
6		16.117	1518301	71355		VB
7		18.817	354458	32687		BB
8		28.717	16597	2098		BB
9		31.967	41230	4687		BB
10		32.567	107938	2454		BB
11		36.633	3763801	256381		BV
12		37.383	2135643	127492		VV
13		37.933	3054	972		VB
14		38.233	16226	2010		BB
15		38.950	8424624	387355		BV

7/14

FIG. 7




Peak Results

#	Name	Ret Time (min)	Area (uV*sec)	Height (uV)	Amount	Int Type
1		4.067	2434486	185800		BV
2		4.483	16280311	1058547		VV
3		4.833	3864081	191585		VV
4		5.600	706286	46936		VV
5		5.983	6703449	371298		VV
6		7.133	451038	24299		VV
7		7.617	542790	22245		VB
8		9.600	3068571	128855		BV
9		10.333	151779	12552		VV
10		10.767	284984	25596		VV
11		11.017	919890	80160		VV
12		11.350	108494	10375		VV
13		11.650	738559	61334		VV
14		12.033	705972	48248		VV
15		12.200	429100	36385		VV

8/14

FIG. 8




Peak Results

#	Name	Ret Time (min)	Area (uV*sec)	Height (uV)	Amount	Int Type
1		4.067	11142185	841146		BV
2		4.467	42897717	1567808		VV
3		5.333	2771843	185077		VV
4		5.750	16970479	962668		VV
5		6.433	1506454	80128		VV
6		6.800	1187124	68430		VV
7		7.150	1105355	55641		VV
8		7.500	322563	40826		VV
9		7.633	1108215	42173		VV
10		8.183	522250	36801		VV
11		8.400	1110198	40131		VV
12		9.317	7318394	222305		VV
13		10.400	866046	57467		VV
14		10.667	2300590	148511		VV
15		11.050	399236	32665		VV

9/14

FIG. 9




Peak Results

#	Name	Ret Time (min)	Area (uV*sec)	Height (uV)	Amount	Int Type
1		4.083	3547997	287640		BV
2		4.417	13468709	786559		VV
3		4.767	4659330	247452		VV
4		5.750	8516445	470707		VV
5		6.317	2011722	70109		VV
6		7.200	883132	30217		VB
7		8.150	94619	7076		BB
8		9.017	439910	25556		BV
9		9.517	3872051	120729		VV
10		10.333	1190270	78799		VV
11		10.650	1054310	76753		VV
12		11.033	385789	28539		VV
13		11.333	761432	56564		VV
14		11.700	1033818	69004		VV
15		11.950	384784	35582		VV

10/14

FIG. 10




Peak Results

#	Name	Ret Time (min)	Area (uV*sec)	Height (uV)	Amount	Int Type
1		4.083	10518737	792810		BV
2		4.367	14687929	1410889		VV
3		4.533	22637504	1494339		VV
4		5.163	3593396	219436		VV
5		5.717	22692299	1152174		VV
6		6.817	960777	60477		VV
7		7.150	682488	44596		VV
8		7.500	1795219	58004		VV
9		8.250	1518279	43057		VV
10		9.250	7251773	190341		VV
11		10.367	1000343	60821		VV
12		10.633	1192302	77226		VV
13		11.050	2788523	178468		VV
14		11.417	6160036	248690		VV
15		12.200	4008326	298350		VV

11/14

FIG. 11



Peak Results

#	Name	Ret Time (min)	Area (uV*sec)	Height (uV)	Amount	Int Type
1		4.100	2979946	236299		BV
2		4.450	15028113	921410		VV
3		4.817	4812815	249684		VV
4		5.550	814070	71678		VV
5		5.850	9688029	563550		VV
6		6.600	914291	48992		VV
7		7.000	272597	28204		VV
8		7.250	1918070	53043		VV
9		8.267	1161101	29288		VV
10		9.367	9258559	294071		VV
11		10.617	903487	62562		VV
12		10.833	1216206	83275		VV
13		11.250	178790	15563		VV
14		11.550	532841	42407		VV
15		11.867	1315340	70286		VV

12/14




FIG. 12

13/14




FIG. 13

14/14





FIG. 14

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB99/02029

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl. 7: G01N 33/68		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC: G01N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPIDS, MEDLINE: renal, kidney, albumin, globulin#, glycoprotein#, urine, intact, degraded, degradation, fragment#, modified, break(w)down, protein#		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 514,928 A2 (WAKAMOTO PHARMACEUTICAL CO., LTD.), 25 November 1992 - see whole document	1-20
X	DE 4,336,498 A1 (BENDER & CO. GmbH), 27 April 1995 - see abstract and whole document	1-20
X	JP 6082446 A (WAKAMOTO PHARMACEUTICAL CO., LTD.), 22 March 1994 - see abstract	1-20
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search 27 April 2000		Date of mailing of the international search report - 9 MAY 2000
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929		Authorized officer  ISOBEL TYSON Telephone No : (02) 6283 2563

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB99/02029

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, December 1999. 32(12):1525-28. Rivarola, E.W. <i>et al</i> , Transforming growth factor beta activity in urine of patients with type 2 diabetes and diabetic nephropathy - see abstract	1-20
X	CLINICAL SCIENCE, July 1998. 95(1): 67-72. Burne, M.J. <i>et al</i> , Alterations in renal degradation of albumin in early experimental diabetes in the rat: a new factor in the mechanism of albuminuria - see whole document	1-20
X	CLINICAL SCIENCE, December 1997. 93(6): 557-64. Osicka, T.M. <i>et al</i> , Fractional clearance of albumin is influenced by its degradation during renal passage - see abstract	1-20
X	PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, December 1997. 216(3): 414-23. Sabatino, B. and Van Liew, J.B., The renal handling of IgG in the aging rat and in experimental kidney disease - see whole document	1-20
X	CLINICAL SCIENCE, July 1997. 93(1): 65-72. Osicka, T.M. and Comper, W.D., Protein degradation during renal passage in normal kidneys is inhibited in experimental albuminuria - see abstract	1-20
X	KIDNEY INTERNATIONAL, February 1991. 39(2): 307-11. Ohta, K. <i>et al</i> , Urinary excretion of endothelin-1 in normal subjects and patients with renal disease - see whole document	1-20
X	JOURNAL OF CHROMATOGRAPHY, 29 July 1988. 429: 315-44. Weber, M.H., Urinary protein analysis - see abstract	1-20
X	CLINICAL NEPHROLOGY, March 1979. 11(3): 140-41. Blainey, J.D. and Terry, J.M., Urinary fibrinogen degradation products and differential protein clearances in renal disease - see whole document	1-20
X	BRITISH MEDICAL JOURNAL, 22 February 1975. 1(5955): 419-22. Hall, C.L. <i>et al</i> , Urinary fibrin-fibrinogen degradation products in nephrotic syndrome - see whole document	1-20

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/IB99/02029

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report			Patent Family Member				
EP	514928	CA	2080250	DE	69221666	DK	514928
		ES	2104770	JP	5302922	US	5246835
DE	4336498	NONE					
JP	6082246	NONE					
							END OF ANNEX